Oral systemic corticosteroids in children with acute asthma exacerbations: a systematic review and network meta-analysis

Guardado en:
Detalles Bibliográficos
Publicado en:Archives of Disease in Childhood (Jun 2025), p. archdischild-2024-327523
Autor principal: Amagasa, Shunsuke
Otros Autores: Utsumi, Shu, Okajima, Kie, Uematsu, Satoko
Publicado:
BMJ Publishing Group LTD
Materias:
Acceso en línea:Citation/Abstract
Full Text + Graphics
Full Text - PDF
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

MARC

LEADER 00000nab a2200000uu 4500
001 3216698427
003 UK-CbPIL
022 |a 0003-9888 
022 |a 1468-2044 
024 7 |a 10.1136/archdischild-2024-327523  |2 doi 
035 |a 3216698427 
045 2 |b d20250601  |b d20250630 
084 |a 270345  |2 nlm 
100 1 |a Amagasa, Shunsuke  |u Department of Emergency and Transport Medicine, National Center for Child Health and Development, Setagaya-ku, Tokyo, Japan 
245 1 |a Oral systemic corticosteroids in children with acute asthma exacerbations: a systematic review and network meta-analysis 
260 |b BMJ Publishing Group LTD  |c Jun 2025 
513 |a Journal Article 
520 3 |a ObjectiveTo evaluate the efficacy differentials among corticosteroid regimens by type, dosage and duration, we conducted a systematic review and network meta-analysis of randomised controlled trials (RCTs).MethodsWe searched four databases from their inception to March 2024 and included RCTs that evaluated oral corticosteroids for asthma exacerbations in young people aged <21 years. We compared six regimens (dexamethasone (DEXA) 0.3 mg/kg/day administered for 1 day, DEXA 0.6 mg/kg/day for 1 day, DEXA 0.6 mg/kg/day for 2 days, prednisolone (PSL) 1.0 mg/kg/day for 3 days, PSL 1.0–1.5 mg/kg/day for 5 days and PSL 2.0 mg/kg/day for 5 days). Primary outcome was relapse within 14 days, defined as unplanned visit to an emergency department or primary care physician.ResultsEleven studies involving 2353 patients were analysed in our quantitative synthesis. There were no significant differences in the relapse rates among 15 comparisons of six regimens. As part of the results, the network estimate showed that DEXA (0.3 mg/kg/day×1 day) compared with PSL (1.0 mg/kg/day for 3 days) had a risk ratio (RR) of 0.99 (95% CI 0.56 to 1.74), and DEXA (0.6 mg/kg/day for 2 days) compared with PSL (1.0–1.5 mg/kg/day×5 days) had an RR of 1.29 (95% CI 0.84 to 1.98). The certainty of the evidence for the included comparisons was low to very low.ConclusionIn this network meta-analysis, there were no significant differences in the efficacy of commonly used corticosteroid regimens for acute exacerbations in childhood asthma. Short-term oral DEXA may be an acceptable alternative to a longer course of PSL.PROSPERO registration numberCRD 42023449189. 
653 |a Prednisolone 
653 |a Clinical trials 
653 |a Emergency medical care 
653 |a Intervention 
653 |a Asthma 
653 |a Web portals 
653 |a Dexamethasone 
653 |a Pediatrics 
653 |a Drug dosages 
653 |a Corticosteroids 
653 |a Dual energy X-ray absorptiometry 
653 |a Corticoids 
653 |a Sensitivity analysis 
653 |a Children 
653 |a Comparative studies 
653 |a Steroids 
653 |a Meta-analysis 
653 |a Primary care 
653 |a Systematic review 
653 |a Physicians 
653 |a Clinical outcomes 
653 |a Social 
653 |a Patients 
653 |a Meta Analysis 
653 |a Evidence 
653 |a Computer Oriented Programs 
653 |a Search Strategies 
653 |a Medical Services 
653 |a Information Seeking 
653 |a Computer Software Reviews 
653 |a Statistical Analysis 
653 |a Comparative Analysis 
653 |a Protocol Materials 
653 |a Networks 
700 1 |a Utsumi, Shu  |u Department of Emergency and Critical Care Medicine, Graduate School of Biomedical &amp; Health Sciences, Hiroshima University, Higashihiroshima, Hiroshima, Japan 
700 1 |a Okajima, Kie  |u Department of Emergency and Transport Medicine, National Center for Child Health and Development, Setagaya-ku, Tokyo, Japan 
700 1 |a Uematsu, Satoko  |u Department of Emergency and Transport Medicine, National Center for Child Health and Development, Setagaya-ku, Tokyo, Japan 
773 0 |t Archives of Disease in Childhood  |g (Jun 2025), p. archdischild-2024-327523 
786 0 |d ProQuest  |t Science Database 
856 4 1 |3 Citation/Abstract  |u https://www.proquest.com/docview/3216698427/abstract/embedded/6A8EOT78XXH2IG52?source=fedsrch 
856 4 0 |3 Full Text + Graphics  |u https://www.proquest.com/docview/3216698427/fulltextwithgraphics/embedded/6A8EOT78XXH2IG52?source=fedsrch 
856 4 0 |3 Full Text - PDF  |u https://www.proquest.com/docview/3216698427/fulltextPDF/embedded/6A8EOT78XXH2IG52?source=fedsrch